Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Net Income towards Common Stockholders of $118.4 million for Q1 2026, up 62.34% year-over-year from $72.9 million in Q1 2025, and up 118.93% quarter-over-quarter from $54.1 million in Q4 2025.
Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Net Income towards Common Stockholders for 13 consecutive years, with $118.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 62.34% year-over-year to $118.4 million; the TTM figure through Mar 2026 stood at $279.0 million (up 9.72% YoY), while the FY2025 annual figure was $233.6 million, down 25.25% from the prior year.
- Net Income towards Common Stockholders improved to $118.4 million in Q1 2026 per LNTH's latest filing, from $54.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $132.0 million in Q3 2023 and bottomed at -$119.2 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged $59.8 million across 5 years, with a median of $62.1 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 196.37% — and 2024, when it jumped 4769.26%.
- Lantheus Holdings' Net Income towards Common Stockholders stood at -$119.2 million in 2022, then soared by 185.05% to $101.4 million in 2023, then sank by 111.63% to -$11.8 million in 2024, then jumped by 558.76% to $54.1 million in 2025, then jumped by 118.93% to $118.4 million in 2026.
- Business Quant data shows LNTH's Net Income towards Common Stockholders at $118.4 million in Q1 2026, $54.1 million in Q4 2025, and $27.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 75.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.03 Mn |
| Mar 31, 2026 | 118.42 Mn |
| Dec 31, 2025 | 54.09 Mn |
| Sep 30, 2025 | 27.77 Mn |
| Jun 30, 2025 | 78.76 Mn |
| Mar 31, 2025 | 72.95 Mn |
| Dec 31, 2024 | -11.79 Mn |
| Sep 30, 2024 | 131.09 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 101.36 Mn |
| Sep 30, 2023 | 131.96 Mn |
| Jun 30, 2023 | 94.13 Mn |
| Mar 31, 2023 | -2.81 Mn |
| Dec 31, 2022 | -119.19 Mn |
| Sep 30, 2022 | 61.23 Mn |
| Jun 30, 2022 | 43.06 Mn |
| Mar 31, 2022 | 42.96 Mn |
| Dec 31, 2021 | -40.22 Mn |
| Sep 30, 2021 | -13.42 Mn |